Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch :
Am J Nurs. 2022 May 1;122(5):18. doi: 10.1097/01.NAJ.0000830720.20631.21.
The labeling for transmucosal buprenorphine products will now include a warning that the drug may cause serious dental problems such as tooth decay, cavities, oral infections, and tooth loss.Nurses and NPs should complete an oral history and assessment prior to patients beginning treatment. Patients should be informed of these potential adverse effects and encouraged to receive regular dental care.
黏膜下丁丙诺啡产品的标签现在将包含一项警告，即该药物可能导致严重的牙齿问题，如龋齿、蛀牙、口腔感染和牙齿脱落。护士和执业护士在患者开始治疗前应完成口腔病史和评估。应告知患者这些潜在的不良反应，并鼓励他们定期进行口腔护理。
